Exposure Definition in Case-Control Studies of Cervical Cancer Screening: A Systematic Literature Review.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
22
03
2021
revised:
14
06
2021
accepted:
08
09
2021
pubmed:
17
9
2021
medline:
5
3
2022
entrez:
16
9
2021
Statut:
ppublish
Résumé
The first step in evaluating the effectiveness of cervical screening is defining exposure to screening. Our aim was to describe the spectrum of screening exposure definitions used in studies of the effectiveness of cervical screening. This systematic review included case-control studies in a population-based screening setting. Outcome was incidence of cervical cancer. Three electronic databases were searched from January 1, 2012 to December 6, 2018. Articles prior to 2012 were identified from a previous review. The qualitative synthesis focused on describing screening exposure definitions reported in the literature and the methodologic differences that could have an impact on the association between screening and cervical cancer. Forty-one case-control studies were included. Six screening exposure definitions were identified. Cervical cancer risk on average decreased by 66% when screening exposure was defined as ever tested, by 77% by time since last negative test, and by 79% after two or more previous tests. Methodologic differences included composition of the reference group and whether diagnostic and/or symptomatic tests were excluded from the analysis. Consensus guidelines to standardize exposure definitions are needed to ensure evaluations of cervical cancer screening can accurately measure the impact of transitioning from cytology to human papillomavirus-based screening and to allow comparisons between programs.
Identifiants
pubmed: 34526301
pii: 1055-9965.EPI-21-0376
doi: 10.1158/1055-9965.EPI-21-0376
pmc: PMC8643309
mid: NIHMS1741373
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2154-2166Subventions
Organisme : NCI NIH HHS
ID : UM1 CA221940
Pays : United States
Organisme : Cancer Research UK
ID : C8162/A27047
Pays : United Kingdom
Informations de copyright
©2021 The Authors; Published by the American Association for Cancer Research.
Références
Acta Cytol. 1997 Jul-Aug;41(4):1103-6
pubmed: 9250306
Br J Cancer. 2003 Jul 7;89(1):88-93
pubmed: 12838306
Int J Cancer. 2020 Mar 1;146(5):1230-1240
pubmed: 31107987
Int J Epidemiol. 1998 Jun;27(3):370-6
pubmed: 9698122
Int J Cancer. 2009 Aug 1;125(3):525-9
pubmed: 19449379
Med J Aust. 1996 Mar 4;164(5):270-3
pubmed: 8628160
Br J Cancer. 1996 Apr;73(8):1001-5
pubmed: 8611418
J Natl Cancer Inst. 2008 May 7;100(9):622-9
pubmed: 18445828
Br J Cancer. 2004 May 4;90(9):1784-6
pubmed: 15150597
Int J Cancer. 2006 Sep 1;119(5):1095-101
pubmed: 16586444
Int J Cancer. 1984 Jul 15;34(1):5-9
pubmed: 6746118
Int J Epidemiol. 1990 Sep;19(3):539-45
pubmed: 2135870
Am J Epidemiol. 1976 May;103(5):512-7
pubmed: 1274953
Lancet. 1984 Oct 6;2(8406):779-82
pubmed: 6148523
Int J Cancer. 2016 Sep 1;139(5):1040-5
pubmed: 27096255
Int J Cancer. 2020 Aug 1;147(3):887-896
pubmed: 31837006
Int J Epidemiol. 1987 Sep;16(3):362-6
pubmed: 3667032
J Clin Epidemiol. 1988;41(6):531-41
pubmed: 3385455
Jpn J Cancer Res. 1988 Dec;79(12):1269-75
pubmed: 3148596
PLoS Med. 2014 Jan;11(1):e1001585
pubmed: 24453946
Syst Rev. 2013 May 24;2:35
pubmed: 23706117
IARC Sci Publ. 1986;(76):111-23
pubmed: 3570398
Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):553-60
pubmed: 23549399
BMJ. 2000 May 27;320(7247):1468
pubmed: 10827061
Int J Epidemiol. 1992 Dec;21(6):1050-6
pubmed: 1336485
Clin Ter. 2016 Jul-Aug;167(4):124-39
pubmed: 27598026
J Natl Cancer Inst. 1998 Jan 7;90(1):50-7
pubmed: 9428783
IARC Sci Publ. 1986;(76):125-31
pubmed: 3570399
Biomed Res Int. 2015;2015:605375
pubmed: 26180804
J Natl Cancer Inst. 1980 May;64(5):1263-72
pubmed: 6767876
J Med Screen. 2011;18(3):147-53
pubmed: 22045824
Br J Cancer. 2020 Jul;123(1):155-160
pubmed: 32362659
BMJ. 1994 May 28;308(6941):1407-11
pubmed: 8019250
Cancer Causes Control. 2008 Aug;19(6):569-76
pubmed: 18286380
BMJ. 2009 Jul 28;339:b2968
pubmed: 19638651
Am J Epidemiol. 1992 Apr 1;135(7):817-23
pubmed: 1595681
Open Med. 2009;3(3):e140-7
pubmed: 21603052
Br Med J (Clin Res Ed). 1986 Sep 13;293(6548):659-64
pubmed: 3092971
J Clin Epidemiol. 1988;41(1):21-6
pubmed: 3335869
Ann Epidemiol. 1993 Jan;3(1):93-8
pubmed: 8287163
Int J Cancer. 1999 Sep 9;82(6):804-9
pubmed: 10446445
Cancer. 2003 Dec 25;99(6):336-41
pubmed: 14681940
Obstet Gynecol. 1989 Dec;74(6):838-43
pubmed: 2586947
Acta Obstet Gynecol Scand. 2000 Mar;79(3):221-6
pubmed: 10716304
Cancer Causes Control. 2013 Sep;24(9):1653-60
pubmed: 23744043
Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1354-61
pubmed: 22665576
Int J Epidemiol. 1988 Sep;17(3):501-8
pubmed: 3209326
Tohoku J Exp Med. 1995 Mar;175(3):171-8
pubmed: 7792786
J Clin Epidemiol. 1989;42(10):1003-11
pubmed: 2809650
Br Med J (Clin Res Ed). 1985 May 25;290(6481):1543-6
pubmed: 3924157
Am J Epidemiol. 1998 Aug 1;148(3):292-7
pubmed: 9690367
Int J Epidemiol. 2003 Aug;32(4):573-7
pubmed: 12913031
Gynecol Oncol. 1990 Jul;38(1):76-80
pubmed: 2354830
Cad Saude Publica. 2012 Oct;28(10):1841-53
pubmed: 23090165
Eur J Cancer Prev. 2007 Dec;16(6):564-7
pubmed: 18090131
Int J Cancer. 1999 Sep 24;83(1):55-8
pubmed: 10449608
Am J Epidemiol. 1999 Jan 1;149(1):1-4
pubmed: 9883787
J Epidemiol Community Health. 1990 Mar;44(1):47-51
pubmed: 2348148
Cancers (Basel). 2020 Jul 28;12(8):
pubmed: 32731340
Cancer Detect Prev. 1989;13(5-6):337-42
pubmed: 2743356